Biomarkers such as VEGF expression levels [51], high tumor mutational burden (TMB) [52], and tumor-infiltrating lymphocyte (TIL) density [53] are being investigated as tools to predict which patients are most likely to benefit from combination strategies. The gene discussed is VEGFA; the disease is neoplasm.